Xinkanghe has completed its Series B+ financing and is fully committed to advancing the research and development of innovative drugs.

2023In July of the year, Xinkanghe Biopharmaceutical completed a new round of financing exceeding 100 million yuan, led by Suzhou Gaotejia Xinyinhui Fund, with follow-up investments from well-known financial institutions such as Beijing Life Park Venture Capital, Guangzhou Xintai, and Yangzhou Fengsheng. Existing shareholders like Hetang Innovation, Northern Light Venture Capital, and Chende Capital continued to inject funds. The funds raised in this round will mainly be used to advance clinical trials and the production of related samples, and to continue non-clinical pharmaceutical research and other early-stage R&D projects.

Xinkanghe Biopharmaceutical was established in 2015, founded by internationally renowned immunologist Academician Dong Chen. The company is based on cutting-edge international research results, guided by precise innovation, focusing on the development of macromolecular drugs in the fields of autoimmune diseases and immuno-oncology, and is committed to creating innovative drugs with independent intellectual property rights that originate from China and target the global market, providing patients with globally pioneering or best-in-class treatment options.

CEO of Xinkanghe Biopharmaceutical, Wang Yaningstated: "We thank all investors for their trust and support for Xinkanghe, and also thank existing shareholders for their continuous increase in holdings. We will do our utmost to advance the clinical development of the company's core products, and we look forward to our innovative drugs demonstrating breakthrough potential in high-quality clinical validation. We firmly believe that with the support of excellent capital, our innovative projects will bring more and better choices to patients.""

Teng Yuhang, Executive Partner of Gaotejia, stated:"Autoimmune diseases are a field that Gaotejia has long focused on, and the Chinese market has a large population of autoimmune patients. Founder Academician Dong Chen is an internationally renowned immunologist with significant discoveries in immune tolerance and inflammatory diseases. We are honored to work with the Xinkanghe team led by Academician Dong Chen and witness the rise of China's innovative power."

Xue Yuan, Partner of Zhongfazhan Lingchuang/Life Park Venture Capital Fundstated: "Xinkanghe is a company driven by original innovation, with a profound understanding of scientific mechanisms and a professional drug R&D and execution team. The Life Park Venture Capital Fund is committed to finding scientists and entrepreneurs who can change the world, creating real social value together. We are very optimistic about the leading scientific research capabilities of the Xinkanghe team and believe that the company will present higher value and growth potential in the future, addressing unmet clinical needs for patients."

Guo Kai, Managing Director of Hetang Venture Capitalstated: "It is an honor to accompany and witness the growth of Xinkanghe all the way. As an early investor in the development of Xinkanghe, Hetang highly recognizes the company's core team and innovative technology platform. The recent clinical performance of the products has also given us great confidence in the company's future development. We hope to work with the Xinkanghe team to create high-quality innovative drugs that benefit a wide range of patients."

Xinkanghe Biopharmaceutical has established a rich product line around autoimmune diseases and tumor immunity, with most products being internationally leading or even globally pioneering. The fastest progress is in the core product IL-17A/F antibody drug XKH004.XKH004is used for the treatment of psoriasis and ankylosing spondylitis, in strong cooperation with Lizhu Group. Both parties have completed clinical phase II and reached the primary research endpoint, and the projectphase III clinical research planhas passed the review of the CDE's EOP2 communication meeting and will officially start subject enrollment in the second half of this year.

The globally pioneering XKH001is independently developed by the company and is the world's first IL-25 targeted antibody drug (First-in-Class) to enter clinical trials, used for the treatment of asthma and other autoimmune and inflammatory diseases. This project has obtained clinical trial approvals in both China and the United States and has completed phase I a trials.The trials on healthy subjects showed good safety and tolerance, and pharmacokinetic data supports the exploration of a 4-week dosing regimen in subsequent clinical trials.This drug will provide a new effective treatment option for patients with globally refractory or resistant inflammatory and autoimmune diseases.

XKH002It is a first-in-class humanized IgG4 monoclonal antibody that blocks B7S1, specifically binding to B7S1 and effectively blocking the inhibitory effect of B7S1 on T cell proliferation and immune response, helping to restore and enhance the body's anti-tumor immune response, and has broad-spectrum anti-cancer potential. It has now obtained clinical trial approvals in both China and the United States, and the company will rapidly advance the clinical development of this product.